- Home
- CANF vs YMAT Comparison
CANF vs YMAT Comparison
Compare CANF & YMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | YMAT |
|---|---|---|
| Founded | 1994 | 1970 |
| Country | Israel | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.3M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CANF | YMAT |
|---|---|---|
| Price | $3.40 | $1.98 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | 25.5K | ★ 46.3K |
| Earning Date | 03-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,715,455.50 | N/A |
| Revenue Next Year | $101.06 | N/A |
| P/E Ratio | ★ N/A | $10.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.24 |
| 52 Week High | $10.40 | $6.45 |
Technical Indicators
Market Signals| Indicator | CANF | YMAT |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 57.71 |
| Support Level | $2.87 | $0.33 |
| Resistance Level | $3.60 | $2.29 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 72.34 | 68.81 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About YMAT J-Star Holding Co. Ltd. Ordinary Shares
J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.